The UK inhalable drug market is anticipated to grow at a CAGR of 2.0% over the forecast period. The key aspect that drives the growth of the market includes the rising prevalence of various respiratory and non- respiratory diseases and the increasing geriatric population. Besides, the inclination of the people towards the sedentary lifestyle along with unhealthy eating habits such as smoking accelerates the prevalence of several respiratory diseases such as COPD and asthma, which ultimately aids in the growth of the market. In addition, increasing R&D and investments by big pharmaceutical companies in life science research along with innovations are likely to propel the growth of the market in the country.
A full report of UK Inhalable Drugs Market is available at: https://www.omrglobal.com/industry-reports/uk-inhalable-drugs-market
Further, recent developments by the companies in the country are also encouraging market growth. Some of the key players operating in the industry include F. Hoffmann-La Roche Ltd., Novartis AG, AstraZeneca Plc, and others. The outbreak of COVID-19 has encouraged the manufacturers to develop novel drugs, including inhalable drugs. For instance, in July 2020, Synairgen Plc, a UK-based drug development company developed an inhaled formulation of interferon beta that aided in reducing the risk of developing severe diseases in COVID-19 patients. Thus, such launches and innovations by the players in the country are likely to encourage market growth.
To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/uk-inhalable-drugs-market
Market Coverage
- Market number available for – 2019-2026
- Base year- 2019
- Forecast period- 2020-2026
- Segment Covered- By Application and By Route of Administration
- Country Covered- UK
- Competitive Landscape- Hoffmann-La Roche Ltd., GlaxoSmithKline Plc, Novartis AG, AstraZeneca Plc, and Synairgen Plc
Key questions addressed by the report
- What is the market growth rate?
- Which segment dominates the market in the base year?
- Which segment will project the fastest growth in the market?
- How COVID-19 impacted the market?
o Recovery Timeline
o Deviation from the pre-COVID-19 forecast
o Most affected segment
- Who is the leader in the market?
- How players are addressing challenges to sustain growth?
- Where is the investment opportunity?
UK Inhalable Drugs Market – Segmentation
By Application
- Respiratory Diseases
- Non- Respiratory Diseases
By Route of Administration
- Nasal
- Mouth
This release has been published on OMR Industry Journal. OMR Industry Journal is not responsible for any content included in this release.
